FMP
NASDAQ
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
4.68 USD
-0.27 (-5.77%)
Valuation Date:
May 2, 2024 4:00 PM
Share Price on Valuation Date
$4.68
Stock Beta
0.697
Shares Outstanding
138148000